Ascendiant Capital Markets Forecasts PSTV Q2 Earnings

Posted by Stanley Muller on Jun 11th, 2026

Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) – Equities research analysts at Ascendiant Capital Markets lowered their Q2 2026 earnings estimates for shares of Plus Therapeutics in a report issued on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings per share of ($0.92) for the quarter, down from their prior estimate of ($0.89). Ascendiant Capital Markets currently has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($3.66) per share. Ascendiant Capital Markets also issued estimates for Plus Therapeutics’ Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.77) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($2.81) EPS.

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.

A number of other research firms have also issued reports on PSTV. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $56.40.

View Our Latest Stock Analysis on Plus Therapeutics

Plus Therapeutics Stock Performance

NASDAQ:PSTV opened at $5.39 on Thursday. The stock has a market capitalization of $37.10 million, a P/E ratio of -2.34 and a beta of 1.38. The company has a 50 day moving average price of $5.65 and a 200 day moving average price of $8.46. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42.

Institutional Investors Weigh In On Plus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PSTV. Jane Street Group LLC acquired a new stake in Plus Therapeutics during the 2nd quarter worth approximately $41,000. Scientech Research LLC acquired a new stake in Plus Therapeutics during the 3rd quarter worth approximately $100,000. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the 3rd quarter valued at $46,000. Geode Capital Management LLC raised its holdings in shares of Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after purchasing an additional 589,544 shares in the last quarter. Finally, L1 Global Manager Pty Ltd purchased a new stake in shares of Plus Therapeutics during the 4th quarter worth $1,167,000. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

(Get Free Report)

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.